BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shuang C, Weiguang Y, Zhenkun F, Yike H, Jiankun Y, Jing X, Xinghan L, Yue L, Dalin L. Toll-like receptor 5 gene polymorphism is associated with breast cancer susceptibility. Oncotarget 2017;8:88622-9. [PMID: 29179462 DOI: 10.18632/oncotarget.20242] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Narayanankutty A. Toll-like Receptors as a Novel Therapeutic Target for Natural Products Against Chronic Diseases. Curr Drug Targets 2019;20:1068-80. [PMID: 30806312 DOI: 10.2174/1389450120666190222181506] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
2 Shi D, Liu W, Zhao S, Zhang C, Liang T, Hou G. TLR5 is a new reporter for triple-negative breast cancer indicated by radioimmunoimaging and fluorescent staining. J Cell Mol Med 2019;23:8305-13. [PMID: 31576678 DOI: 10.1111/jcmm.14707] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jiang W, Han Y, Liang T, Zhang C, Gao F, Hou G. Down-Regulation of Toll-Like Receptor 5 (TLR5) Increased VEGFR Expression in Triple Negative Breast Cancer (TNBC) Based on Radionuclide Imaging. Front Oncol 2021;11:708047. [PMID: 34336694 DOI: 10.3389/fonc.2021.708047] [Reference Citation Analysis]
4 Shi D, Zhao S, Jiang W, Zhang C, Liang T, Hou G. TLR5: A prognostic and monitoring indicator for triple-negative breast cancer. Cell Death Dis 2019;10:954. [PMID: 31852883 DOI: 10.1038/s41419-019-2187-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
5 Narayanankutty A, Sasidharan A, Job JT. Targeting Toll like Receptors in Cancer: Role of TLR Natural and Synthetic Modulators. CPD 2020;26:5040-53. [DOI: 10.2174/1381612826666200720235058] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
6 Flórez-Álvarez L, Ruiz-Perez L, Taborda N, Hernandez JC. Toll-like receptors as a therapeutic target in cancer, infections and inflammatory diseases. Immunotherapy 2020;12:311-22. [PMID: 32237938 DOI: 10.2217/imt-2019-0096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
7 Guo Y, Liu H, Chen Y, Yan W. The effect of allicin on cell proliferation and apoptosis compared to blank control and cis-platinum in oral tongue squamous cell carcinoma. Onco Targets Ther 2020;13:13183-9. [PMID: 33402832 DOI: 10.2147/OTT.S178718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Shi S, Xu C, Fang X, Zhang Y, Li H, Wen W, Yang G. Expression profile of Toll‑like receptors in human breast cancer. Mol Med Rep 2020;21:786-94. [PMID: 31789409 DOI: 10.3892/mmr.2019.10853] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]